Operating Segments

12 Months Ended

Dec. 31, 2014

Operating Segments [Abstract]

Operating Segments

Note 10. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended December 31,
	2014			2013
Revenues
Vaccines/BioDefense	$	6,756,388		$	3,003,822
BioTherapeutics		286,628			220,330
Total	$	7,043,016		$	3,224,152
Income (loss) from Operations
Vaccines/BioDefense	$	807,164		$	(1,666,130	)
BioTherapeutics		(7,674,381	)		(3,069,998	)
Corporate		(3,894,132	)		(2,420,414	)
Total	$	(10,761,349	)	$	(7,156,542	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	39,625		$	37,981
BioTherapeutics		199,196			190,033
Corporate		6,966			2,057
Total	$	245,787		$	230,071
Interest Income
Corporate	$	1,310		$	1,960
Stock-Based Compensation
Vaccines/BioDefense	$	114,920		$	80,432
BioTherapeutics		193,926			250,431
Corporate		411,304			472,197
Total	$	720,150		$	803,060

	As of December 31,
	2014		2013
Identifiable Assets
Vaccines/BioDefense	$	1,025,220	$	1,870,414
BioTherapeutics		204,308		386,721
Corporate		5,724,720		6,008,320
Total	$	6,954,248	$	8,265,455